



Read all of this leaflet carefully before you start taking this medicine because it contains important information for you

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See Section 4.

What is in this leaflet:

1. What Zalkya is and what it is used for
2. What you need to know before you take Zalkya
3. How to take Zalkya
4. Possible side effects
5. How to store Zalkya
6. Contents of the pack and other information



1. WHAT ZALKYA IS AND WHAT IT IS USED FOR

Zalkya is a medicine used for the treatment of endometriosis (painful symptoms due to displaced tissue of the lining of the womb). Zalkya contains a hormone, the progestogen dienogest.

2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZALKYA

DO NOT take Zalkya if you:

- are suffering from a **blood clot** (thromboembolic disorder) in your veins. This may occur, for example, in the blood vessels of the legs (deep vein thrombosis) or the lungs (pulmonary embolism). See also "Zalkya and venous blood clots" below;
- have or have ever had a **severe arterial disease**, including cardiovascular disease, such as a **heart attack, stroke or heart disease** which causes a reduced blood supply (angina pectoris). See also "Zalkya and arterial blood clots" below
- have **diabetes** with blood vessel damage;
- have or have ever had **severe liver disease** (and your liver function values have not returned to normal); Symptoms of liver disease may be yellowing of the skin and/or itching of the whole body;
- have or have ever had a **benign or malignant liver tumour**;
- suffer or have ever suffered, or if it is suspected that you suffer from a **malignant** sex-hormone dependent tumour such as cancer of the breast or the genital organs;
- have any unexplained **vaginal bleeding**;
- are **allergic** to dienogest or any of the other ingredients of this medicine (*listed in section 6*).

If any of these conditions appear for the first time while using Zalkya, stop taking it at once and consult your doctor.

Warnings and precautions

Talk to your doctor or pharmacist before taking Zalkya.

You must not use hormonal contraceptives of any form (tablet, patch, intrauterine system) while taking Zalkya.

Zalkya is NOT a contraceptive. If you want to prevent pregnancy, you should use condoms or other non- hormonal contraceptive precautions.

In some situations you need to take special care while using Zalkya, and your doctor may need to examine you regularly. Tell your doctor if any of the following conditions applies to you:

- If you:
- have ever had a **blood clot** (venous thromboembolism) or anyone in your immediate family has had a blood clot at a relatively early age;
 - have a close relative who has had **breast cancer**;
 - have ever suffered from **depression**;
 - have **high blood pressure** or develop high blood pressure while taking Zalkya;
 - develop a **liver disease** while taking Zalkya.
- Symptoms may include yellowing of the skin or eyes or itching all over your body. Inform your doctor also if such symptoms occurred during a previous pregnancy;
- have diabetes or had **diabetes** temporarily during previous pregnancy;
 - have ever had **chloasma** (golden-brown patches on the skin, particularly of the face); if so, avoid too much exposure to the sun or ultraviolet radiation;
 - suffer from **pain in your lower abdomen** while taking Zalkya.

While taking Zalkya your chance of becoming pregnant is reduced because Zalkya may affect ovulation. If you become pregnant while taking Zalkya you are at a **slightly increased risk** of having an extrauterine pregnancy (the embryo develops outside the womb). Tell your doctor before you start taking Zalkya, if you had an extrauterine pregnancy in the past or have an impaired function of the Fallopian tubes.

Zalkya and serious uterine bleeding

Uterine bleeding, for example in women with a condition where the mucous membrane of your uterus (endometrium) grows into the muscle layer of your uterus, called adenomyosis uteri or **benign tumours of the womb** sometimes called uterine fibroids (uterine leiomyomata), may become worse with the use of Zalkya.

If bleeding is heavy and continuous over time, this may lead to low red blood cell levels (anemia), which may be severe in some cases. In the event of anemia, you should discuss with your doctor if you should stop taking Zalkya.

Zalkya and changes in bleeding pattern

Most women treated with Zalkya experience changes in their menstrual bleeding pattern (see section 4, possible side effects).

Zalkya and venous blood clots

Some studies indicate that there may be a slight, but not statistically significant, increased risk of a **blood clot in the legs (venous thromboembolism)** associated with the use of preparations with progestogens like Zalkya. Very rarely, blood clots may cause serious permanent disabilities or may even be fatal.

The risk of a **venous blood clot** increases:

- with increasing age;
- if you are overweight;
- if you or one of your close relatives had a blood clot in the leg (thrombosis), lung (pulmonary embolism), or other organ at a young age;
- if you must have surgery, if you have had a serious accident or if you are immobilized for a long time. It is important to tell your doctor in advance that you are using Zalkya as the treatment may have to be stopped. Your doctor will tell you when to start Zalkya again. This is usually about two weeks after you are back on your feet.

Zalkya and arterial blood clots

There is little evidence for an association between preparations with progestogens like Zalkya and an increased risk of a blood clot in, for example, the blood vessels of the heart (heart attack) or the brain (stroke). In women with hypertension the risk of stroke may be slightly enhanced by these preparations.

The risk of an **arterial blood clot** increases:

- **if you smoke. You are strongly advised to stop smoking when you use Zalkya, especially if you are older than 35 years;**
- if you are overweight;
- if one of your close relatives had a heart attack or stroke at a young age;
- if you have high blood pressure.

Talk to your doctor before taking Zalkya.

Stop taking Zalkya and contact your doctor immediately if you notice possible signs of a blood clot, such as:

- severe pain and/or swelling in one of your legs;
- sudden severe pain in the chest which may reach the left arm;
- sudden breathlessness;
- sudden cough without an obvious cause;
- any unusual, severe or long-lasting headache or worsening of migraine;
- partial or complete blindness or double vision;
- difficulty in speaking or inability to speak;
- giddiness or fainting;
- weakness, strange feeling, or numbness in any part of the body.

Zalkya and cancer

It is not clear from the data currently available whether or not Zalkya increases the risk of breast cancer. Breast cancer has been observed slightly more often in women taking hormones compared to those not taking hormones, but it is not known whether this is caused by the treatment. For example, it may be that more tumours are detected and detected earlier in women taking hormones because they are examined by their doctor more often. The occurrence of breast tumours becomes gradually less after stopping the hormone treatment. **It is important to regularly check your breasts** and you should contact your doctor if you feel any lump.

In rare cases, benign liver tumours, and in even fewer cases malignant liver tumours have been reported in women taking hormones. Contact your doctor if you have unusually severe stomach pain.

Zalkya and osteoporosis

Changes in bone mineral density (BMD)

The use of Zalkya may affect the strength of the bone of adolescents (12 to under 18 years). If you are under 18 your doctor will, therefore, carefully weigh the benefits and risks of using Zalkya for you as an individual patient, taking into account possible risk factors for bone loss (osteoporosis).

If you use Zalkya, it will help your bones if you have an adequate intake of calcium and vitamin D either via your food or via supplements.

If you have an increased risk of getting osteoporosis (weakening of bones due to loss of bone minerals), your doctor will carefully weigh the risks and benefits of treatment with Zalkya because Zalkya has a moderate suppressing effect on the production of oestrogen (another type of female hormone) by your body.

Children and adolescents

Zalkya is not for use in girls before menarche (first menstrual bleeding).

The use of Zalkya may affect the strength of the bone of adolescents (12 to under 18 years). If you are under 18 your doctor will, therefore, carefully weigh the benefits and risks of using Zalkya for you as an individual patient, taking into account possible risk factors for bone loss (osteoporosis).



Other medicines and Zalkya

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Also tell any other doctor or dentist who prescribes another medicine (or the pharmacist) that you are taking Zalkya.

Some medicines can have an influence on the blood levels of Zalkya and can make it less effective, or can cause undesirable effects.

These include:

- medicines used for the treatment of:
 - **epilepsy** (e.g. phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate);
 - **tuberculosis** (e.g. rifampicin);
 - **HIV and Hepatitis C Virus infections** (so-called protease inhibitors and non-nucleoside reverse transcriptase inhibitors such as ritonavir, nevirapine, efavirenz);
 - **fungal infections** (griseofulvin, ketoconazole);
- the herbal remedy St. John's wort.

Zalkya with drink

During Zalkya treatment, you should avoid drinking grapefruit juice, because this may increase the levels of Zalkya in your blood. This may increase the risk of getting side effects.

Laboratory tests

If you need a blood test, tell your doctor or the laboratory staff that you are taking Zalkya, because Zalkya can affect the results of some tests.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Do not take Zalkya if you are pregnant or breast-feeding.

Driving and using machines

No effects on the ability to drive and use machines have been observed in users of Zalkya.

3. HOW TO TAKE ZALKYA

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

For adults, the usual dose is 1 tablet per day.

The following statements apply to Zalkya unless otherwise prescribed by your doctor. Please follow these instructions, otherwise you will not fully benefit from Zalkya.

You can start treatment with Zalkya on any day of your natural cycle.

Adults: take one tablet every day, preferably at the same time with some liquid as needed. When a pack is finished the next one should be started without interruption. Continue to take the tablets also on days of menstrual bleeding.

There is no experience with Zalkya treatment for more than 15 months in patients with endometriosis.

If you take more Zalkya than you should

There have been no reports of serious harmful effects from taking too many Zalkya tablets at one time. However, if you are concerned, contact your doctor.

If you forget to take Zalkya or suffer from vomiting or diarrhoea

Zalkya will be less effective if you miss a tablet. If you miss one or more tablets, take one tablet only as soon as you remember, and then continue next day taking the tablet at your usual time.

If you vomit within 3-4 hours of taking Zalkya or you have severe diarrhoea, there is a risk that the active substance in the tablet will not be taken up by your body. The situation is almost the same as forgetting a tablet. After vomiting or diarrhoea within 3-4 hours of taking Zalkya, you should take another tablet as soon as possible.

Do not take a double dose to make up for a forgotten tablet.

If you stop taking Zalkya

If you stop taking Zalkya, your original endometriosis symptoms may return. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are more common during the first months after start of intake of Zalkya and usually disappear with continued use. You may also experience changes in your bleeding pattern, such as spotting, irregular bleeding or your periods may stop completely.

Common (affecting between 1 and 10 in every 100 users)

- weight gain;
- depressed mood, problems sleeping, nervousness, loss of interest in sex, or changed mood;
- headache or migraine;
- nausea, abdominal pain, wind, swollen tummy or vomiting;
- acne or hair loss;
- back pain;

- breast discomfort, ovarian cyst or hot flushes;
- uterine/vaginal bleeding including spotting;
- weakness or irritability.

Uncommon (affecting between 1 and 10 in every 1,000 users)

- anemia;
- weight loss or increase in appetite;
- anxiety, depression or mood swings;
- imbalance in the autonomic nervous system (controls unconscious bodily functions, e.g. perspiration) or disturbed attention;
- dry eye;
- tinnitus;
- unspecific circulatory problems or uncommon palpitations;
- low blood pressure;
- shortness of breath;
- diarrhoea, constipation, abdominal discomfort, inflammation of the stomach and intestines (gastrointestinal inflammation), inflammation of the gums (gingivitis);
- dry skin, excessive sweating, severe itching of the whole body, male pattern hair growth (hirsutism), brittle nails, dandruff, dermatitis, abnormal hair growth, hypersensitive response to light or problems with skin pigmentation;
- pains in your bones, muscle spasms, pains and/or a sensation of heaviness in your arms and hands or legs and feet;
- urinary tract infection;
- vaginal thrush, dryness of the genital area, vaginal discharge, pelvic pain, atrophic inflammation of the genitals with discharge (atrophic vulvovaginitis), or a lump or lumps in the breast;
- swelling due to fluid retention.

Additional side effects in adolescents (12 to under 18 years):
loss of bone density.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard

5. HOW TO STORE ZALKYA

This medicinal product does not need a specific storage condition. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the packaging after "EXP.". The expiry date refers to the last day of that month.

Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Zalkya contains

The active substance is dienogest. Each tablet contains 2 mg dienogest.

The other ingredients are

Core: cellulose microcrystalline, pregelatinised maize starch, crospovidone, povidone K25, silica colloidal anhydrous, magnesium stearate

Film coating: AquaPolish white: hypromellose, hydroxypropyl-cellulose, cottonseed oil, hydrogenated, talc, titanium dioxide (E171)

What Zalkya looks like and contents of the pack

Zalkya tablets are white, round, 7.1 mm wide and 3.4 mm high film coated tablets.

14 white film-coated tablets are packed in PVC (250 µm)-Aluminium (20 µm) push-through-blister.

Two blisters of 14 tablets are then packed in a PET (Polyethylene Terephthalate)/ aluminium/ PE (Polyethylene) pouch, which protects tablets from humidity.

One or three pouches are packed in a carton box.

Pack sizes: 28 and 84 film-coated tablets

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

STRAGEN UK Ltd
Castle Court
41 London Road
Reigate
Surrey RH2 9RJ
Phone: +44 (0)1737 735029
Email: info@stragenuk.com

Manufacturer

HAUPT PHARMA Münster GmbH
Schleebüggenkamp 15
48159 Münster
Germany

This leaflet was last revised in 06/2019.

stragen